Obesity and the Liver: Developmental Perspectives

ABSTRACT

Obesity now affects 15% of children and adolescents in the United States. Many of the complications of obesity are seen in children, including fatty liver disease, gallstones, hyperlipidemia, insulin resistance, and type 2 diabetes. Infants and children also have unique susceptibilities to and manifestations of liver disease caused by total parenteral nutrition. In addition to genetic and environmental influences on obesity, there is increasing evidence supporting the idea of “metabolic programming,” in which environmental influences at critical periods during development have permanent effects on an individual's predisposition to obesity and metabolic disease. Understanding the role the liver plays in the development and expression of the metabolic program will provide important insight into the pathogenesis and treatment of fatty liver disease, and of obesity itself.

Development - obesity - fatty liver steatohepatitis

REFERENCES

• 1 Ogden C L, Flegal K M, Carroll M D, Johnson C L. Prevalence and trends in overweight among US children and adolescents, 1999-2000.  JAMA. 2002;  288 1728-1732
• 2 McLellan F. Obesity rising to alarming levels around the world.  Lancet. 2002;  359 1412
• 3 Whitaker R C, Wright J A, Pepe M S et al.. Predicting obesity in young adulthood from childhood and parental obesity.  N Engl J Med. 1997;  337 869-873
• 4 Must A, Jacques P F, Dallal G E et al.. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935.  N Engl J Med. 1992;  327 1350-1355
• 5 Fagot-Campagna A, Pettitt D J, Engelgau M M et al.. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective.  J Pediatr. 2000;  136 664-672
• 6 Dean H J, Young T K, Flett B, Wood-Steiman P. Screening for type 2 diabetes in aboriginal children in Northern Canada.  Lancet. 1998;  352 1523-1524
• 7 Dablea D, Hanson R L, Bennett P H et al.. Increasing prevalence of type 2 diabetes in American Indian children.  Diabetologia. 1998;  41 904-910
• 8 Sinha R, Fisch G, Teague B et al.. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity.  N Engl J Med. 2002;  346 802-810
• 9 American Diabetes Association . Type 2 diabetes in children and adolescents.  Diabetes Care. 2000;  23 381-389
• 10 Cook J S, Hoffman R P, Stene M A, Hansen J R. Effects of maturational stage on insulin sensitivity during puberty.  J Clin Endocrinol Metab. 1993;  77 725-730
• 11 Moran A, Jacobs D, Steinberger D R et al.. Insulin resistance during puberty: results from clamp studies in 357 children.  Diabetes. 1999;  48 2039-2044
• 12 Murphy M J, Metcalf B S, Voss L D et al.. Girls at five are intrinsically more insulin-resistant than boys: The Programming Hypothesis Revisited-the EarlyBird study (EarlyBird 6).  Pediatrics. 2004;  113 82-86
• 13 Arsalnian S, Suprongsin C. Insulin sensitivity, lipids, and body composition in childhood: is “syndrome X” present?.  J Clin Endocrinol Metab. 1996;  81 1058-1062
• 14 Travers J H, Jeffers B W, Bloch C A et al.. Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children.  J Clin Endocrinol Metab. 1995;  80 172-178
• 15 Strauss R S, Barlow S E, Dietz W H. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents.  J Pediatr. 2000;  136 727-733
• 16 Kinugasa A, Tsunamoto K, Furukawa N et al.. Fatty liver and its fibrous changes found in simple obesity of children.  J Pediatr Gastroenterol Nutr. 1984;  3 408-414
• 17 Fishbein M H, Miner M, Mogren C, Chalekson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis.  J Pediatr Gastroenterol Nutr. 2003;  36 54-61
• 18 Franzese A, Vajro P, Aregenziana A et al.. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population.  Dig Dis Sci. 1997;  42 1428-1432
• 19 Molleston J P, White F, Teckman J, Fitzgerald J F. Obese children with steatohepatitis can develop cirrhosis in childhood.  Am J Gastroenterol. 2002;  97 2460-2462
• 20 Kusonoki T, Sadawada T, Ohya N. Fatty liver associated with simple obesity of childhood.  Jpn Med J. 1975;  2667 25-28
• 21 Rashid M, Roberts E A. Nonalcoholic steatohepatitis in children.  J Pediatr Gastroenterol Nutr. 2000;  30 48-53
• 22 Schwimmer J B, Deutsch R, Rauch J et al.. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease.  J Pediatr. 2003;  143 500-505
• 23 Kawasaki T, Hashimoto N, Kikuchi T et al.. The relationship between fatty liver and hyperinsulinemia in obese Japanese children.  J Pediatr Gastroenterol Nutr. 1997;  24 317-321
• 24 Angulo P. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
• 25 Garcia-Monzon C, Martin-Perez E, Iacono E L et al.. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity.  J Hepatol. 2000;  33 716-724
• 26 Nakao K, Nakata K, Ohtsubo N et al.. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults.  Am J Gastroenterol. 2002;  97 1796-1801
• 27 Vajro P, Fontanella A, Perna C et al.. Persistent hyperaminotransferasemia resolving after weight reduction in obese children.  J Pediatr. 1994;  125 239-241
• 28 Bellentani S, Saccoccio G, Masutti F et al.. Prevalence of and risk factors for hepatic steatosis in Northern Italy.  Ann Intern Med. 2000;  132 112-117
• 29 Marchesini G, Brizi M, Bianchi G et al.. Metformin in non-alcoholic steatohepatitis.  Lancet. 2001;  358 893-894
• 30 Caldwell S H, Hespenheide E E, Redick J A et al.. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.  Am J Gastroenterol. 2001;  96 519-525
• 31 Promrat K, Lutchman G, Uwaifo G I et al.. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.  Hepatology. 2004;  39 188-196
• 32 Lavine J E. Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study.  J Pediatr. 2000;  136 734-738
• 33 Kigici M, Gultten M, Gurel S et al.. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.  Can J Gastroenterol. 2003;  17 713-718
• 34 Lavine J. Pediatric initiatives within the nonalcoholic steatohepatitis-clinical research network (NASH-CRN).  J Pediatr Gastroenterol Nutr. 2003;  37 220-221
• 35 Kumar R, Nguyen K, Shun A. Gallstones and common bile duct calculi in infancy and childhood.  Aust N Z J Surg. 2000;  70 188-191
• 36 Holcomb Jr G W, Holcomb GW I II. Cholelithiasis in infants, children and adolescents.  Pediatr Rev. 1990;  11 268-274
• 37 Miltenburg D M, Schaffer 3rd R, Breslin T, Brandt M L. Changing indications for pediatric cholecystectomy.  Pediatrics. 2000;  105 1250-1253
• 38 Wesdorp I, Bosman D, de Graaff A et al.. Clinical presentations and predisposing factors of cholelithiasis and sludge in children.  J Pediatr Gastroenterol Nutr. 2000;  31 411-417
• 39 Barker D JP. Fetal origins of coronary heart disease.  BMJ. 1995;  311 171-174
• 40 Barker D JP, Hales C N, Fall C H et al.. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome x): relation to reduced fetal growth.  Diabetologia. 1993;  36 62-67
• 41 Rich-Edwards J W, Stampfer M J, Manson J E et al.. Birthweight and risk of cardiovascular disease in a cohort of women followed up since 1976.  BMJ. 1997;  315 396-400
• 42 Ravelli A CJ, van der Meulen J HP, Michels R PJ et al.. Glucose tolerance in adults after prenatal exposure to famine.  Lancet. 1998;  351 173-177
• 43 Hales C N, Barker D JP. The thrifty phenotype hypothesis.  Br Med Bull. 2001;  60 5-20
• 44 Van Assche F A, Holemans K, Aerts L. Long-term consequences for offspring of diabetes during pregnancy.  Br Med Bull. 2001;  60 173-182
• 45 Ozanne S E, Hales C N. Lifespan: catch-up growth and obesity in male mice.  Nature. 2004;  427 411-412
• 46 Hales C N, Desai M, Ozanne S E, Crowther N J. Fishing in the stream of diabetes: from measuring insulin to the control of fetal organogenesis.  Biochem Soc Trans. 1996;  24 341-350
• 47 Burns S P, Desai M, Cohen R D et al.. Gluconeogenesis, glucose handling, and structural changes in livers of the adult offspring of rats partially deprived of protein during pregnancy and lactation.  J Clin Invest. 1997;  100 1768-1774
• 48 Angelico M, Della Guardia P. Hepatobiliary complications associated with total parenteral nutrition.  Aliment Pharmacol Ther. 2000;  14 54-57
• 49 Capron J-P, Gineston J-L, Herve M-A, Braillon A. Metronidazole in prevention of cholestasis associated with total parenteral nutrition.  Lancet. 1983;  1 446-447
• 50 Pappo I, Bercovier H, Berry E et al.. Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat.  JPEN J Parenter Enteral Nutr. 1995;  19 80-82
• 51 Sugiura T, Tashiro T, Yamamori H et al.. Effects of total parenteral nutrition on endotoxin translocation and extent of the stress response in burned rats.  Nutrition. 1999;  15 570-575
• 52 Nakano K, Chijiiwa K, Noshiro H, Hirota I, Yamasaki T. Human gallbladder bile becomes lithogenic during short-term intravenous hyperalimentation.  J Surg Res. 1992;  53 396-401
• 53 Lindor K D, Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report.  Gastroenterology. 1991;  101 250-253
• 54 Duerksen D R, Van Aerde J E, Gramlich L et al.. Intravenous ursodeoxycholic acid reduces cholestasis in parenterally fed newborn piglets.  Gastroenterology. 1996;  111 1111-1117
• 55 Sitzmann J V, Pitt H A, Steinorn P A et al.. Cholecystokinin prevents parenteral nutrition-induced biliary sludge in humans.  Surg Gynecol Obstet. 1990;  170 25-31